Fig. 2: Prevalence and outcomes of gBRCA1/2 pathogenic/likely pathogenic variants carriers according to eligibility for adjuvant olaparib. | npj Breast Cancer

Fig. 2: Prevalence and outcomes of gBRCA1/2 pathogenic/likely pathogenic variants carriers according to eligibility for adjuvant olaparib.

From: Clinicopathological characteristics and eligibility for adjuvant olaparib of germline BRCA1/2 mutation carriers with HER2-negative early breast cancer

Fig. 2

a iDFS for patients eligible and ineligible for adjuvant olaparib; b RFS for patients eligible and ineligible for adjuvant olaparib; c Proportion of eligible and ineligible patients among gBRCA PV carriers with TNBC; d Proportion of eligible and ineligible patients among gBRCA PV carriers with HR+/HER2− breast cancer. iDFS invasive disease-free survival, RFS recurrence-free survival, HER2− human epidermal growth factor receptor 2 negative, HR+ hormone receptor positive, PV pathogenic/likely pathogenic, TNBC triple-negative breast cancer.

Back to article page